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High health gain patients with asthma: a cross-sectional study
analysing national Scottish data sets
Mome Mukherjee 1, Bright I. Nwaru1,2,3, Ireneous Soyiri 1, Ian Grant4 and Aziz Sheikh1
Studies have shown that a small proportion of patients have particularly high needs and are responsible for disproportionally high
disease burden. Estimates suggest that 2–5% of patients are high users of healthcare for their health gain. Such patients in Scotland
are referred to as high health gain (HHG) patients. We wanted to investigate if there were HHG individuals with asthma in Scotland.
We analysed data from the Scottish Health Survey (2010–11), and primary and National Health Survey (NHS) secondary healthcare
and administrative data sets (2011–12). In all, 1,379,690 (26.0%) and 836,135 (15.8%) people reported to have ever had and
currently have symptoms suggestive of asthma, respectively; 369,868 (7.0%) people reported current symptomatic clinician-
diagnosed asthma. 310,050 (5.6%) people had clinician-reported-diagnosed asthma; there were 289,120 nurse consultations,
215,610 GP consultations, 9235 accident and emergency visits (0.2% people), 8263 ambulance conveyances (0.2% people), 7744
inpatient episodes (0.1% people), 3600 disability allowance claims (0.1% people), 187 intensive care unit (ICU) episodes and 94
deaths from asthma. From our study a maximum of about 9.4% of asthma patients (n= 29,145), which is 0.5% of the Scottish
population, and from the National Review of Asthma Deaths’ estimate (10% hospitalised), a minimum of nine people had severe
asthma attacks that needed acute hospital attendance/admission. We found that although a high proportion of the Scottish
population had symptoms suggestive of asthma and clinician diagnosed asthma, only a small proportion of asthma patients
experienced exacerbations that were severe enough to warrant hospital attendance/admission in any given year. Developing risk
prediction models to identify these HHG patients has the potential to both improve health outcomes while substantially reducing
healthcare expenditure.
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INTRODUCTION
Asthma is now one of the most common long-term conditions in
economically-developed countries, with the prevalence being
particularly high in English-speaking nations.1 There is also a
growing body of work showing that asthma is responsible for
considerable morbidity and, in some cases, mortality.2
While there are a number of investigations on the epidemiology
and healthcare utilisation of asthma in specialist clinical settings
and some using more population-based approaches,3–9 there
have been relatively few attempts to provide a national overview
of asthma and its impact.2 Such analyses are potentially important
to support health policy and planning, as well as inform
deliberations on whether there are subsets of the asthma
population that are particularly at high risk of poor outcomes
and thus need focussed care. This subset of the population is also
sometimes known as ‘high-need, high-cost’ (HNHC) patients and
in Scotland as ‘high risk individuals’ (HRI) or ‘high health gain’
(HHG) individuals.10–16
Building on our recent work studying asthma in the UK,2 we
sought to undertake a more detailed analysis of asthma in
Scotland, taking advantage of the considerable data assets
available, in order to provide the ﬁrst detailed national proﬁle of
asthma in Europe. This work will enable us to ascertain if there is a
HHG group of individuals with asthma.
RESULTS
Prevalence
In 2010–11, an estimated 26.0% (95% CI 21.7–30.4; equivalent to
1,379,690 people, 95% CI 1,148,779–1,610,601) of the Scottish
population reported to ever had experienced symptoms of
asthma in their lifetime; 15.8% (95% CI: 12.4–19.2; equivalent to
836,135 people, 95% CI 655,872–1,016,398) reported to have
experienced symptoms of asthma in the last 12 months preceding
the survey; 13.6% (95% CI 10.5–16.7; equivalent to 746,542 people,
95% CI 554,883–884,271) reported to have had clinician-
diagnosed asthma in their lifetime; 9.9% (95% CI 7.3–12.5;
equivalent to 524,883 people, 95% CI 385,831–663,935) reported
to have had clinician-diagnosed symptomatic asthma in the last
12 months; and 7.0% (95% CI 4.8–9.2; equivalent to 369,868
people, 95% CI 251,933–487,802) reported to have had clinician-
diagnosed-and-treated asthma in the last 12 months. In 2011–12,
an estimated 5.6% (95% CI 5.5–5.7; equivalent to 310,050 people,
95% CI 305,182–314,918) had clinician-diagnosed asthma and
6.0% (95% CI 6.0–6.0; equivalent to 319,091 people, 95% CI
319,091–319,091) had clinician-diagnosed-and-treated asthma.
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Healthcare and societal care utilisation
In 2011–12, there were 289,120 nurse consultations (95% CI
284,422–293,818); 215,610 GP consultations (95% CI
211,563–219,657); 9235 A&E attendances (95% CI 8358–10,113);
8263 ambulance conveyances; 7744 inpatient episodes; 4575 out
of hour calls; 3600 claimed DLA; there were 187 ICU episodes and
94 deaths.
Since this was a cross-sectional study, we could not ascertain
what proportion of asthma patients contributed to the healthcare
use. However, with the conservative assumption of one event or
service use to one person only, and using the lowest denominator
(i.e., 310,050 as the number of people with clinician-diagnosed
asthma reported by GPs), then we can estimate that 93.2% (95% CI
91.7–94.8) had nurse consultations; 69.5% had GP (95% CI
68.2–70.8); 1.5% called out-of-hours service (95% CI 1.4–1.5);
3.0% attended A&E (95% CI 2.7–3.3); 2.7% used an ambulance
service (95% CI 2.6–2.7); 2.5% had a hospital admission (95% CI
2.4–2.6); 1.2% claimed DLA (95% CI 1.1–1.2); 0.1% were admitted
in an ICU (95% CI 0.1–0.1); and 0.03% died with asthma as an
underlying reason (95% CI 0.02–0.04). This implies that in Scotland
there was a maximum of about 9.4% of asthma patients (sum of
3% A&E attendances, 2.7% ambulance conveyances, 2.5% hospital
admission, 1.2% DLA claims, 0.1% ICU, 0.03% deaths), equivalent
to 29,145 people, which is 0.5% of the population, who had severe
asthma, which required resource intensive ambulance services,
acute hospital services (i.e., A&E/hospitalisation/ICU admission),
costly DLA beneﬁts or led to death.
The asthma population proﬁle, describing asthma prevalence,
healthcare utilisation and outcomes, including mortality, is
illustrated using a pyramid graph below (Fig. 1). The stack of the
pyramid is depicting the severity of the disease at population
level. The bottom of the pyramid is showing the number of people
who had ever experienced symptoms of asthma in their lifetime
(n= 1,379,690), whereas the tip is showing the number of people
who eventually died due to asthma as the underlying reason (n=
94).
DISCUSSION
Statement of principal ﬁndings
This national level proﬁle of asthma epidemiology and health and
social care utilisation in Scotland has found that even though the
annual prevalence of symptoms suggestive of asthma (15.8% of
the Scottish population) or of clinician-diagnosed asthma itself
(5.6% of the Scottish population) is high in Scotland, only a small
minority of patients (0.5% of the Scottish population) experience
events severe enough to lead to emergency hospital attendance/
admission, with far fewer still who experience ICU admission or
have a fatal episode in any given year. This suggests that there
may be potential to risk-stratify at a population level and develop
cost-effective interventions in this high risk group.
Strengths
This study provides the ﬁrst detailed national picture of asthma in
Scotland using population representative survey data and routine
data from a national health system and administrative data, with
coverage from cradle-to-grave. The estimates produced in this
exercise are slightly higher than our previous exercise.2 Are these
estimates better? Our previous exercise was to compare nations
across the UK. Hence, we had used European Standard Population
(ESP) 2013 as the reference population when we age standardised.
But when we are focussing on Scotland and not comparing to
elsewhere, using the population estimate of Scotland (SMYEP) as
the reference is a logical choice. If we compare ESP and SMYEP, we
will ﬁnd that: (a) population distribution by gender in ESP is
identical, whereas in SMYEP it varies (online Appendix 2); and (b)
SMYEP had less young population and higher older population
compared to ESP. Thus, by using SMYEP split by 5-year age-groups
and gender as the reference population, the estimates are not
only different, but also higher. The reference population used to
produce the estimates is appropriate for this particular study,
hence these estimates are more appropriate for this purpose.
Limitations
We did not have cohort data to investigate if there is a small group
of asthma patients who have high-need and thus use healthcare
services more. In the absence of cohort data, the layout of this
cross-sectional study amply suggests that there is a tiny group of
asthma patients who have severe asthma and use resource
intensive or costly services. Since this was not a cohort study, one
step of the pyramid did not necessarily contribute to the next. Our
estimates are based on conservative assumptions. Thus, we
presume that the proportion of asthma patients who had severity
or fatality are even smaller than we estimated here (9.4%).
Nevertheless, this study lends us a hypothesis of the proportion of
HNHC/HRI/HHG asthma patients, i.e., a maximum of 9.4% of
asthma patients could be HNHC/HRI/HHG. Some data gaps we
found were unavailability of out-of-hours GP services data, lack of
diagnosis data in outpatient clinics, people who got Xolair (drug
used to treat severe asthma), people who used private medical
services for their asthma. Although we had good coverage of data,
there were two NHS health boards, which did not contribute data
to A&E2 and thus were excluded in this analysis.
Interpretation in the light of the previous literature
Of the 16 outcome measures reported here, nine outcomes had
the same values as in our previous exercise,2 since either they
Fig. 1 Asthma population proﬁle in Scotland in 2011–12 (patient reported 2010–2011): asthma prevalence, healthcare utilisation and
outcomes
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were real absolute numbers and cannot/should not be adjusted to
population level, example number of calls to NHS 24, number of
ambulance trips, number of day-case/inpatient episodes, number
of deaths, or they were already adjusted to the respective
database population, example GP consultations, nurse consulta-
tions and annual prevalence of clinician-reported-and-diagnosed
asthma, all from Practice Team Information (PTI) primary care
database, or the data did not have age-sex distribution and hence
could not be adjusted, example annual prevalence of clinician-
reported-diagnosed-and-treated asthma from Quality and Out-
comes Framework (QOF), Disability living allowance (DLA). The
other seven estimates generated from using SMYEP are more
appropriate when looking into Scotland alone. These seven new
estimates were for ﬁve prevalence estimates from Scottish Health
Survey, A&E and ICU. For the ﬁve prevalence estimates from
Scottish Health Survey, the number of respondents who had said
yes to the question (n), number of respondents (N), ASR (95% CI),
were provided for Scotland in the previous exercise.2 The age and
gender adjusted rates were different when SMYEP was used, and
thus the estimated number reported in this manuscript. A&E
estimates for the two HBs, which did not submit patient level data
were generated adjusting to the respective HB’s estimated
population and were estimated for Scotland using SMYEP. We
did not have the number of children under 15 in adult ICUs (from
ICNARC) for England, Wales and Northern Ireland. But we had
small number of children who were 15 and older in paediatric
ICUs in PICANet and children under 15 in adult ICUs in SICSAG for
Scotland. These small numbers had to be excluded in our earlier
exercise to follow the same principle of inclusion across the four
nations.2 Since this manuscript is about Scotland speciﬁc estimate,
we could use these small numbers by combining data from
PICANet and SICSAG.
We found that while 310,050 people who were diagnosed for
asthma by clinicians (5.6% people (95% CI: 5.5–5.7)), 319,091
people (6.0% people (95% CI: 6.0–6.0)) had clinician-diagnosed-
and-treated asthma as per the ﬁnancial incentive based QOF
register. Perhaps there was an issue of possible over-diagnosis or
over-labelling, as was found in studies on children and adults in
the Netherlands and Canada, respectively.17,18 There is likely to be
scope for diagnostic clariﬁcation in the population with asthma
symptoms.
This work shows that only a small proportion (0.5%) of the
Scottish population end up with serious asthma attacks or deaths.
We know from our previous exercise that of the approximately
£92.2 million public expenditure in Scotland for asthma,2 about
£54.5 m (59.1%) was spent on community prescriptions, £14.8 m
(16%) on DLA, £8.6 m (9.3%) on GP consultations, £6.3 m (6.9%) on
inpatient episodes, £4.0 m (4.4%) on nurse consultations, £2.4 m
(2.6%) on ambulance conveyance, £0.9 m (1.0%) on A&E, £0.5 m
(0.5%) on ICU and £0.1 m (0.1%) on out-of-hour calls.2 Due to data
constraints in that exercise we could not calculate cost per patient
for use of each of those healthcare services, which would have
helped us understand resource use of a healthcare service in
monetary units at a person level. However, using our conservative
assumption above, we can estimate that 1.2% people with
clinician-diagnosed asthma who claimed DLA, cost the economy
£14.8 m; 2.5% who had a hospital admission for asthma cost the
economy at least £6.3 m; and 0.1% who were admitted in an ICU
had cost the economy at least £0.5 m.
In the UK-wide review of asthma deaths, NRAD had found that
of the 195 deaths for asthma, 21% had been to A&E and 10% were
hospitalised for their asthma in the 12 months prior to their
deaths. These UK-wide percentages are much higher than our
conservative estimates for Scotland. Yet, if we apply the NRAD
percentages to the Scottish asthma deaths, we reckon of the 94
people who died due to asthma, 20 might had been to A&E and 9
were hospitalised in the year before their death.
Our conservative assumption is too simplistic; in reality there
are re-admissions to hospital, thus the counts of cases do not
necessarily equal counts of patients. Therefore, the proportion of
people using healthcare and social care services is expected to be
lower than the estimates we have computed here. The implication
of this is that there is only a small number of asthma patients who
have high care needs and for whom public expenditure is very
steep. There is thus the potential for risk stratiﬁcation, using
prognostic factor research,19 and case management, to reduce the
risk of hospitalisations, ICU admissions, near death situations and
deaths. Recent work has found that about 2% of patients
contribute to about 50% of healthcare costs in Scotland.15,20
Although our work alludes towards this fact, given the limitations
in the data we could not ascertain this in the asthma patient
population. Making such inference will require a cohort study
design, which will permit investigating whether there is a HNHC/
HRI/HHG asthma patient group in Scotland, and if there is,
estimates of proportions of HHG and HC asthma patients.
Implications for policy, practice and research
This study, through the pyramid structure of the disease portrayal,
very clearly demonstrates that Scotland has both a pressing need
and the data assets needed to address the issue of identifying
HNHC/HRI/HHG patients. Although asthma should in the vast
majority of cases be manageable in primary care contexts, our
study found that in Scotland—despite the NHS spending around
£100m/year—there are nearly 8000 hospitalisations and 100
deaths from asthma/year. Much of this expenditure and poor
outcomes is down to a small percentage of people who are not
always easy to identify and manage. Having studied the overall
patterns of care and costs of asthma in Scotland,2 we now need to
build on this and develop a new tool that allows healthcare
professionals to ﬁnd patients at risk of poor asthma outcomes. We
plan to do this by analysing Scotland’s unique national data sets,
through linkage, to create a cohort of asthma patients to help
understand and identify patients who could gain from better case
management earlier on, than letting them become severely sick
and costly. Once we have found this patient group, we need to
ﬁnd new ways to give them more tailored care, so they do better.
Similar work is also needed in other UK and European nations, to
understand the asthma population proﬁles in each of their
respective nations, for better care and resource allocation.
CONCLUSIONS
Although asthma is common in Scotland, only a relatively small
proportion of those with asthma experience attacks requiring
acute hospital attendance/admission in any given year. It is
important to characterise the relatively small subset of patients
who are experiencing poor asthma outcomes and see if it is
possible to develop and validate prognostic algorithms for
identifying those with severe asthma attacks in Scotland, and
then armed with this information proactively intervene to reduce
the risk of severe, potentially life-threatening asthma attacks.
METHODS
We undertook a national cross-sectional study in Scotland. The STROBE
and RECORD statements were used to guide the reporting of this
manuscript (online Appendix 1).21,22
Data sources used
We undertook secondary analyses of Scottish Health Survey (SHeS) and
National Health Service (NHS) data sets on primary and secondary care and
administrative data.23 SHeS is a series of stratiﬁed, cluster-sampled, cross-
sectional surveys designed to measure the health of a representative
sample of the Scottish population living in private households.24 The NHS
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data sets used were Quality and Outcomes Framework (QOF), Practice
Team Information (PTI), NHS 24, Accident and Emergency (A&E) datamart,
Scottish Ambulance Service (SAS), Scottish Morbidity Records (SMR) for
outpatients (SMR0) and inpatients (SMR1), Paediatric Intensive Care Audit
Network (PICANet) and Scottish Intensive Care Society Audit Group
(SICSAG).23 The administrative data sets used were disability living
allowance (DLA) from Department of Work and Pensions (DWP) and death
registrations from National Records Scotland (NRS).23
All GP practices in Scotland report to QOF, whereby they get ﬁnancial
incentive for providing quality care to their patients, according to the UK
General Medical Services (GMS) contract.25 PTI is a general practitioner (GP)
database comprising a sample of 60 practices representing about 6% of
Scottish GP practices and around 6% of the Scottish patient population.26
NHS 24 is a national telephone triage and advice service across Scotland
during out-of-hour GP service.27 NHS 24 calls are triaged by call-handling
nurses using disease-speciﬁc algorithm to support decision-making. A&E
Table 1. Outcome measures by data sets used for asthma population proﬁle in Scotland—name of data set, population coverage in the data set and
criteria used to select study population from that data set
Outcome Data sets used for Scotland
Name of data set Population coverage Selection criteria for study population
Prevalence Annual prevalence of
clinician-reported-and-
diagnosed asthma
Practice Team
Information (PTI)
Sixty GP practices in National
Health Service (NHS) Scotland
(6% of all GP practices)a
Read codes, version 2, for asthma diagnosisb
Annual prevalence of
clinician-reported-diagnosed-
and-treated asthma
Quality and
Outcomes
Framework (QOF)
All GP practices in NHS
Scotland (about 1000; number
changes slightly with time)
Read codes, version 2, for asthma diagnosisb
Lifetime prevalence of
patient-reported symptoms
suggestive of asthmab
Annual prevalence of patient-
reported symptoms
suggestive of asthmac
Lifetime prevalence of
patient-reported clinician-
diagnosed asthmad
Annual prevalence of patient-
reported clinician-diagnosed
symptomatic asthmae
Annual prevalence of patient-
reported clinician-diagnosed-
and-treated asthmaf
Scottish Health
Survey (SHeS)
National population survey of
randomly sampled private
household
Answer to survey questionsc–g
Primary care-
healthcare
utilisation
GP and nurse consultation Practice Team
Information (PTI)
Sixty Scottish GP practices
(6% of all GP practices)a
Read codes, version 2, for asthma diagnosisa
Out of hours calls NHS 24 All telephone calls to NHS 24
in NHS Scotland
Calls triaged using NHS 24’s asthma-speciﬁc algorithm
Secondary
care—
healthcare
utilisation
Ambulance conveyances Scottish
Ambulance Service
(SAS)
All ambulance conveyances in
Scotland
SAS record had ‘Emergency call-asthma selected’
Accident and emergency
(A&E) visits
Accident and
Emergency
datamart
All hospitals with A&E in NHS
Scotland
ICD-10 codes for asthma,h including ‘R062’ (family history
of asthma) or if the ‘presenting complaint text’ or
‘diagnosis text’ referred to any of the terms asthma,
wheezing, low saturation, chest tightness or shortness of
breath
Inpatient and day-case
episodes (non-psychiatric)
Scottish Morbidity
Records (SMR01)
All hospitals in NHS Scotland ICD-10 codes for asthma as primary reason for admissionh
Paediatric ICU episodes Paediatric Intensive
Care Audit
Network (PICANet)
All paediatric intensive care
units in NHS Scotland
Read codes, version 3, as primary reason for admissioni
Adult ICU episodes Scottish Intensive
Care Society Audit
Group (SICSAG)
All adult intensive care units
in NHS Scotland
APACHE III diagnoses for asthma as primary reason for
admission
Societal Disability living allowance Department for
Work and Pensions
(DWP)
All individuals claiming
beneﬁt in Scotland
ICD-10 codes for asthma as primary reason for admissionh
Deaths National Records of
Scotland (NRS)
All individuals who died in
Scotland
ICD-10 codes for asthma as underlying cause of deathh
aThe total population of PTI GP practhe Scottish population with regards to age, gender and deprivation, and small imbalances due to these demographic and
socio-economic factors are addressed during data analysis through a process of direct standardisation
bRead codes, version 2 listed: http://bmjopen.bmj.com/content/bmjopen/suppl/2014/11/04/bmjopen-2014-006647.DC1/bmjopen-2014-006647supp_appen-
dix2.pdf
c
‘Have you ever had wheezing/whistling in the chest at any time, either now/in the past?’
d
‘Have you had wheezing or whistling in the chest in the last 12 months?’
e
‘Did a doctor ever tell you that you had asthma?’
f
‘Have you had wheezing or whistling in the chest in the last 12 months?’ and ‘Did a doctor ever tell you that you had asthma?’
g
‘Were you treated in the past 12 months for wheeze by GP/nurse at surgery/community/school/district nurse/hospital, consultant/specialist at hospital,
consultant/specialist elsewhere, homoeopath/acupuncturist/other alternative medicine professional?’
hICD-10 codes ‘J 45’ (asthma), ‘J46’ (status asthmaticus)
iRead codes, version 3 listed: http://bmjopen.bmj.com/content/bmjopen/suppl/2014/11/04/bmjopen-2014-006647.DC1/bmjopen-2014-006647supp_appen-
dix3.pdf
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datamart (A&E2) was used for sites, which report patient-level information
from their A&E departments.28 SAS provides ambulance service across
Scotland. All outpatient clinic appointments are recorded in SMR0 and all
hospital discharges in SMR1 across Scotland.29 PICANet is a UK-wide audit
network, which collects data from all paediatric intensive care units (ICU).30
SICSAG is a Scotland-wide audit network that captures data from all adult
ICUs.31 Data from stand-alone HDUs are not included in PICANet or SICSAG.
All records of number of people and amount of DLA were available from
DWP.32 All deaths were registered with NRS.33
Outcome measures
Table 1 below describes the outcome measures by data sets used for
asthma population proﬁle in Scotland, with the name of data set,
population coverage in the data set and criteria used to select study
population from that data set.
SHeS was used to describe the lifetime and annual prevalence of
patient-reported symptoms suggestive of asthma, lifetime prevalence of
patient-reported clinician-diagnosed asthma, annual prevalence of patient-
reported clinician-diagnosed symptomatic asthma and annual prevalence
of patient-reported clinician-diagnosed-and-treated asthma. The relevant
questions used to determine these prevalence outcome measures have
been previously described.2 QOF was used for annual prevalence of
clinician-reported-diagnosed-and-treated asthma.25 PTI was used for
annual prevalence of clinician-reported-and-diagnosed asthma and GP
and nurse consultations, by using Read codes version 2.23,26 Number of
calls for asthma during GP out-of-hours services were obtained from NHS
24.23,27 Only ‘new’ and ‘unplanned return’ type of attendances at A&E were
used, and not when patients had a scheduled visit to A&E clinics, classiﬁed
as ‘recall’ or ‘planned return’. Furthermore, A&E visits were selected based
on ICD-10 codes ‘J45’ (asthma) and ‘J46’ (status asthmaticus), along with
‘R062’ (family history of asthma) or if the ‘presenting complaint text’ or
‘diagnosis text’ referred to any of the terms or textual variations of: asthma,
wheezing, low saturation, chest tightness or shortness of breath.23,28 The
NHS Health Boards of Orkney and Tayside did not submit patient level
information to A&E2, and hence these two regions were excluded from the
A&E analysis. The number of ambulance conveyances for asthma were
obtained from SAS.23,34 SMR0 was not used since diagnoses in outpatient
clinics are not recorded.23,35 Hospital discharge episodes for asthma were
obtained from SMR01, which had ICD-10 codes ‘J45’ and ‘J46’ as the
primary diagnosis.23,35 ICUs discharges for Scottish residents with primary
diagnosis of asthma were obtained from PICANet using Read codes version
3 and from SICSAG using Acute Physiology and Chronic Health Evaluation
(APACHE) III diagnoses.30,31,36 Paediatric and adult ICU episodes have been
added up to generate estimates of ICU episode numbers at population
level. The number of people who received DLA for asthma as their main
disabling condition were available from DWP,32 using ICD-10 codes. The
number of deaths with asthma as the underlying cause of death, using
ICD-10 codes, were available from NRS.37
We had access to anonymised SHeS records at individual respondent
level from the open data source from UK Data Services.24 QOF was
obtained and is available aggregated, at individual GP level. All the other
data, except QOF, were available aggregated by 5-year age-group and
gender to ensure patient conﬁdentiality by data custodians.
Study period
Data from healthcare and administrative data sets were obtained for the
ﬁnancial year 2011–12. The corresponding latest SHeS data for that time
period was for 2010–11.
Analysis
Where the data set referred to a sample of the population, e.g., SHeS, PTI or
to a sub-section of the population, e.g., A&E, estimates were calculated,
and then scaled up to the national population level to determine the
number estimates at national level. Asthma attendances in A&E were not
only missing from two of the 14 NHS Health Boards, but there were also
390 attendances (4.4%) where age/gender information was missing.
Counts of A&E attendances by 5-year age-groups and gender from the
remaining NHS Health Boards and their total population were used to
extrapolate Scotland level numbers, using Scottish mid-year estimate of
population (SMYEP) by age-group and gender. SMYEP in 2010 was
5,262,200 and in 2011 was 5,299,900. A similar scaling up of the SHeS
estimates were done at Scotland level by age-group and gender. Thus,
95% conﬁdence intervals (CI) were calculated for estimates from SHeS, PTI
and A&E, using Poisson approximation.23 Where the data set referred to
the entire national population, e.g., hospital admissions, the number of
episodes or people were taken from the database. Numbers obtained
directly from QOF, NHS 24, SAS, SMR01, PICANet, SICSAG, NRS deaths and
DLA are reported here. Percentage of the population is reported with 95%
CI. Using a pyramid, graph we constructed a national asthma population
proﬁle to describe asthma prevalence, healthcare and societal care
utilisation and outcomes, including mortality.
Ethical approval
Analyses were undertaken using anonymised, aggregated data, for the
entire work. The application for ethics was processed through The
University of Edinburgh’s Centre for Population Health Sciences Research
Ethics Committee; and a self-assessment revealed that no further ethical
permissions were required. For patient level data access we obtained
approvals from the respective Data Custodians.
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(b) Aggregated by year, sex and age-group level (e.g., hospital discharge
data), which are available only to named researchers and cannot be shared
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